Posted by Michael Wonder on 23 Dec 2022
FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma
22 December 2022 - Today, the FDA granted accelerated approval to mosunetuzumab-axgb (Lunsumio, Genentech), a bispecific CD20 directed CD3 T-cell engager for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Mosunetuzumab-axgb was evaluated in GO29781, an open-label, multi-centre, multi-cohort study.
